APP下载

重组人粒细胞集落刺激因子对乳腺癌化疗后骨髓抑制的疗效分析

2017-03-20孔谦

中外医疗 2017年1期
关键词:乳腺癌

孔谦

[摘要] 目的 该文旨在研究探讨应用重组人粒细胞集落刺激因子(recombinant human granulocyte colony-stimulating factor,rhG-CSF)对乳腺癌患者化疗后骨髓抑制的治疗效果。方法 采用回顾性研究,方便选出2013年5月—2016年5月在某医院使用多西他赛(docetaxel)75 mg/m2、环磷酰胺(cyclophosphamide)500 mg/m2化疗方案的100例浸润性乳腺癌患者,在化疗第1个周期结束后1~2 d内皮下注射rhG-CSF为治疗组,化疗后1~2 d内未皮下注射rhG-CSF为对照组,评估两组化疗后骨髓抑制的程度。结果 在应用rhG-CSF的50例患者中,白细胞减少症的发生率为24%,中性粒细胞减少症发生率为20%;在对照组50例患者中,二者发生率分别为80%和70%,差异有统计学意义(P<0.01)。治疗组与对照组化疗前白细胞计数差异无统计学意义(P=0.648>0.05),两组化疗前中性粒细胞计数差异无统计学意义(P=0.104>0.05);化疗后两组白细胞和中性粒细胞计数差异有统计学意义(P<0.01)。 结论 浸润性乳腺癌患者在第一周期化疗后1~2 d内给予rhG-CSF,能减少白细胞降低比率,使骨髓抑制得以减轻,确保化疗顺利进行。

[关键词] 重组人粒细胞集落刺激因子;骨髓抑制;疗效分析

[中图分类号] R737.9 [文献标识码] A [文章编号] 1674-0742(2017)01(a)-0017-03

[Abstract] Objective The purpose of this study was to investigate the effect of recombinant human granulocyte colony-stimulating factor(rhG-CSF)for myelosuppression in patients with breast cancer after chemotherapy. Methods Using retrospective study,Convenient selected 100 cases of invasive breast cancer patients,who use docetaxel 75mg/m2 and cyclophosphamide 500 mg/m2 chemotherapy in the hospital,between May 2013 and May 2016. After first cycles of chemotherapy , within one or two days, the patients were injected rhG-CSF as the treatment group ,on the contrary ,the patient werent injected rhG-CSF as the control group. To evaluate the degree of myelosuppression after chemotherapy. Results The rate of leucopenia was 24% and the rate of neutropenia was 20% in the treatment group,The occurrence rate of the two index was 80% and70% respectively in the control group. There was statistical significance between the two groups(P<0.01).The count of white blood cell and neutrophil was no significant difference between the treatment group(P=0.648>0.05) and the control group before chemotherapy(P=0.104>0.05). After chemotherapy, the count of white blood cell and neutrophil of the two group was statistical significance(P<0.01). Conclusion The application of rhG-CSF in invasive breast cancer patients after first cycles of chemotherapy can reduce the incidence of white blood cell count, reduce the extent and duration of myelosuppression, and ensure the smooth progress of chemotherapy.

[Key words] Recombinant human granulocyte colony-stimulating factor;Myelosuppression; Efficacy analysis

乳腺癌目前是女性最常见的恶性肿瘤之一,威胁着女性的健康。化疗是治疗乳腺癌的重要手段之一,能提高肿瘤患者的无进展生存期和总生存期。但化疗药物在控制肿瘤的同时,也会引起骨髓抑制等不良反应。骨髓抑制常表现为白细胞及中性粒细胞减少,往往使患者的化疗药物减量,甚至不能完成预定化疗周期,严重者威胁患者生命,重则导致患者死亡[1]。重组人粒细胞集落刺激因子(recombinant human granulocyte colony-stimulating factor,rhG-CSF)作用于中性粒细胞的骨髓粒系祖细胞,促使其向成熟的中性粒细胞分化,并促使成熟的中性粒细胞的释放入外周血,快速提升白细胞计数,保证化疗的顺利进行。常……

登录APP查看全文

猜你喜欢

乳腺癌
绝经了,是否就离乳腺癌越来越远呢?
中医治疗乳腺癌的研究进展
乳腺癌的认知及保健
乳腺癌是吃出来的吗
胸大更容易得乳腺癌吗
男人也得乳腺癌
防治乳腺癌吃什么:禽比兽好
别逗了,乳腺癌可不分男女老少!
PI3K在复发乳腺癌中的表达及意义
CD47与乳腺癌相关性的研究进展